Synthetic Biology
Home / Services / By Technology / Protein Engineering Services / Protein Expression and Purification Service / Protein expression in mammalian cells / Custom CHO Cell Protein Expression Service
Trusted by Leading Biopharmaceutical Companies

CHO Cell Expression Services

Industry-leading mammalian expression platform for producing therapeutic proteins with authentic human-like glycosylation. Our CHO cell expression services deliver high-quality, scalable protein production meeting regulatory standards for clinical and commercial applications.

Human-like Glycosylation
GMP Compliant
High Productivity
Learn More

Trusted by leading research and pharmaceutical institutions

MIT
Roche
Johns Hopkins
Amgen
Caltech
Regeneron

Why Choose Us

Industry-standard CHO cell platforms
High-titer fed-batch processes
Complete analytical characterization
Scalable from 1L to 2000L bioreactors

Human-like PTMs

Proper glycosylation and folding for therapeutic proteins

High Titer

Optimized fed-batch processes up to 10 g/L

Regulatory Ready

Complete documentation for IND filings

Approved mAbs
100+
Overview Technology Specifications Workflow Applications FAQ
Service Overview

Industry-Standard CHO Cell Platform

Our CHO cell expression platform combines decades of mammalian cell engineering expertise with state-of-the-art bioprocessing technology for superior therapeutic protein production.

Established Cell Lines

Proprietary CHO-K1, CHO-S, and DG44 cell lines optimized for high-productivity recombinant protein expression. Our cell banks are thoroughly characterized and maintained under strict quality control.

  • Well-characterized host cell lines
  • High transfection efficiency
  • Excellent growth characteristics

Proven Track Record

CHO cells are the gold standard for therapeutic antibody production, with over 100 approved monoclonal antibody products manufactured using this platform. Our service builds on this proven foundation.

  • FDA/EMA validated platform
  • Extensive regulatory experience
  • Comprehensive analytical support

Human-like Glycosylation

Proper sialylation and glycosylation patterns similar to human proteins for enhanced efficacy and safety.

High Titer Processes

Optimized fed-batch and perfusion culture strategies achieving productivities up to 10 g/L.

Scalable Platform

Seamless scale-up from 1L shake flasks to 2000L bioreactors with consistent product quality.

Ready to Produce Your Therapeutic Protein?

Get a customized quote for your CHO expression project.

Technology Platform

Advanced Expression Technologies

Our optimized CHO expression system delivers superior protein quality and productivity.

Optimized Expression Vectors

Proprietary vectors with strong CMV promoters, optimized IRES elements, and selection marker systems for high stable expression.

CMV Promoter DHFR Selection

High-Titer Fed-Batch

Proprietary chemically defined media and feed strategies achieving exceptional volumetric productivity and product quality.

CD Media Fed-Batch

Glycoengineering

Engineered CHO lines with modified glycosylation pathways for enhanced antibody-dependent cellular cytotoxicity (ADCC).

Low Fuc High Sialylation

Quality Control

SEC-HPLC Purity and aggregation analysis
CEX-HPLC Charge variant analysis
Mass Spec Intact mass and peptide mapping
Glycan Analysis HILIC glycan profiling

Purification Services

Protein A Antibody capture purification
Ion Exchange Intermediate polishing step
Size Exclusion Final polishing and formulation
Ultrafiltration Concentration and buffer exchange
Specifications

Flexible Options for Diverse Needs

Comprehensive specifications to meet your research and clinical requirements.

Parameter Research Grade Preclinical Grade GMP Grade
Cell Line CHO-K1, CHO-S CHO-K1, DG44 MCB from qualified bank
Typical Titer 1-5 g/L 3-8 g/L 5-10 g/L
Scale Range 1-10 L 10-200 L Up to 2000 L
Purity >95% >98% >99%
Purification Protein A + buffer exchange Multi-step + analytics Full characterization suite
Turnaround Time 6-10 weeks 10-16 weeks 16-24 weeks
Workflow

Streamlined Development Process

Our proven workflow ensures quality and efficiency at every stage.

1

Vector Construction

Gene cloning and vector preparation

2

Transfection

Cell transfection and pool selection

3

Clone Screening

High-throughput clone evaluation

4

Scale-up

Fed-batch process development

5

Purification

Downstream processing and QC

Applications

Diverse Applications Across Biotechnology

Our CHO expression services support research and development in multiple fields.

Monoclonal Antibodies

CHO cells are the preferred platform for therapeutic antibody production, enabling proper folding, assembly, and human-like glycosylation essential for antibody function and safety.

  • Full-length IgG production
  • Bispecific antibody formats
  • Antibody-drug conjugates (ADC) precursors
  • Enhanced ADCC glycoengineering options
100+
Approved mAb products

Fc-Fusion Proteins

CHO cells produce properly folded and assembled Fc-fusion proteins with appropriate glycosylation for enhanced serum half-life and biological activity.

  • Receptor-Fc fusion proteins
  • Cytokine-Fc constructs
  • Peptide-Fc conjugates
  • Albumin-Fc fusion platforms
10-20x
Extended half-life

Therapeutic Proteins

Beyond antibodies, CHO cells support production of complex therapeutic proteins including enzymes, hormones, and growth factors with proper PTMs.

  • Enzyme replacement therapeutics
  • Hormones and growth factors
  • Cytokines and immune modulators
  • Blood factors and clotting proteins
2000L
Maximum production scale
Testimonials

What Our Clients Say

Trusted by researchers worldwide for quality and reliability.

"The CHO expression service delivered exceptional results for our therapeutic antibody project. The protein quality was outstanding and the team provided excellent technical support throughout the process."

D
Senior Scientist
Biopharmaceutical Company

"We achieved high-titer production of our bispecific antibody that was previously difficult to express. The glycoengineering options were particularly valuable for optimizing ADCC activity."

K
Research Director
Oncology Research Lab

"Professional service with comprehensive analytical support. The quality data package exceeded our expectations and was ready for regulatory submission. A reliable partner for our pipeline."

T
VP Development
Pharmaceutical Company
Scientific Literature

Scientific Foundation

Our platform is backed by peer-reviewed research.

89 Citations

Evidence for co-translational misincorporation of non-canonical amino acid hydroxyproline in recombinant antibodies produced in CHO cell lines

Boddapati S, Gilmore J, Boone K, et al. PLoS ONE. 2020.

Investigation of hydroxyproline misincorporation in CHO-expressed antibodies revealing relationships between proline concentration and sequence variants.

View DOI
47 Citations

A doubly auxotrophic CHO-K1 cell line for the production of recombinant monoclonal antibodies

Zhang Q, Jiang B, Du Z, Chasin LA. Biotechnology and Bioengineering. 2020.

Development of CRISPR-Cas9 engineered dual-auxotrophic CHO-K1 cells for stable high-efficiency monoclonal antibody production.

View DOI
25 Citations

Improving the expression of anti-IL-2Ralpha monoclonal antibody in CHO cells through optimization of expression vector and translation efficiency

Rajabi Rajabibazl M, et al. Journal of Biotechnology. 2020.

Combination of SINEUP and UCOE elements for enhanced therapeutic antibody expression in CHO cells.

View DOI
68 Citations

Advances of Glycometabolism Engineering in Chinese Hamster Ovary Cells

Zhang HY, Fan ZL, Wang TY. Frontiers in Bioengineering and Biotechnology. 2021.

Comprehensive review of CHO cell glycometabolism engineering including carbohydrate uptake, pyruvate metabolism, and mitochondrial optimization.

View DOI
156 Citations

Factors Affecting the Expression of Recombinant Protein and Improvement Strategies in Chinese Hamster Ovary Cells

Multiple authors. Frontiers in Bioengineering and Biotechnology. 2022.

Comprehensive review of factors affecting CHO cell protein expression including genetic engineering, cell engineering, and bioprocess optimization.

View DOI
FAQ

Frequently Asked Questions

Find answers to common questions about our service.

CHO cells are the gold standard for therapeutic protein production due to their ability to perform human-like post-translational modifications, proper protein folding, and assembly. Over 100 FDA-approved monoclonal antibodies have been produced in CHO cells. The platform offers well-established regulatory pathways, scalable production from milliliters to thousands of liters, and proven industrial robustness.
We offer multiple characterized CHO cell lines including CHO-K1, CHO-S, and DG44. Each has specific advantages: CHO-K1 for robust growth and high productivity, CHO-S for rapid expansion and transient expression, and DG44 for dihydrofolate reductase (DHFR) based selection systems. Our team will recommend the optimal line based on your protein requirements.
Typical antibody titers range from 3-10 g/L in optimized fed-batch processes. Expression levels vary depending on the antibody sequence, clone stability, and process conditions. We conduct high-throughput clone screening to identify top producers and optimize culture conditions to maximize volumetric productivity.
Yes, we offer glycoengineering services to modify the glycosylation profile of expressed proteins. Options include low-fucose cell lines for enhanced ADCC activity, high-sialylation platforms for improved serum half-life, and custom glycan profiles for specific therapeutic requirements.
Yes, we offer GMP-compliant manufacturing services from cell bank establishment through final drug substance production. Our facilities support production scales from 200L to 2000L bioreactors with complete regulatory documentation packages suitable for IND filings and clinical trials.
We provide comprehensive analytical characterization including purity by SEC-HPLC, charge heterogeneity by CEX-HPLC, intact mass and peptide mapping by LC-MS, glycan analysis by HILIC-FL, biological activity assays, and additional specialized tests as required. All analytical methods are validated and documentation follows ICH guidelines.

Ready to Start Your Project?

Get a customized quote for your Custom CHO Cell Protein Expression Service project. Our experts will respond within 24 hours.

No obligation
24h response
Expert consultation

Recommended Services

· Custom HEK Cell Protein Expression Service

Related Resources

· Cost and Efficiency Analysis of CRlSPR-Cas9 Knockout Services in Mice and Cell Lines
· Validating CRISPR Knockouts: Best Practices for qPCR, Sequencing, and Functional Assays
· Step-by-Step Guide to Generating CRISPR Knockout Cell Lines for Research
Quick Links

Home

Products

Services

About Us

Contact Us

Follow Us
CONTACT US

USA

Tel:

Email:

Japan

Tel:

Email:

Korea

Tel:

Email:

Copyright © 2026 CD Biosynsis. All rights reserved.